Drug Profile

Sarecycline - NeuroDawn Pharmaceutical

Latest Information Update: 04 Aug 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator NeuroDawn
Class Amides; Antiacnes; Antibacterials; Naphthacenes; Skin disorder therapies; Small molecules; Tetracyclines; Vascular disorder therapies
Mechanism of Action Ribosomal protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Ischaemic stroke

Most Recent Events

04 Aug 2023 Chemical structure information added
08 May 2023 Preclinical trials in Ischaemic stroke in China (PO)
08 May 2023 NeuroDawn Pharmaceutical plans the phase II ESPRIT trial in Ischaemic stroke [PO,Tablet] in April 2023 (NCT05836753)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com